$42.84
-1.83[-4.10%]
At close: May 14
Eisai Co
(OTCPK:ESALF)Latest News for Eisai Co Stock (OTC:ESALF)
Eisai Co Stock (OTC: ESALF)
Categories: All
Friday, March 22, 2024
Friday, December 08, 2023
- Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial CancerVandana Singh - Dec 8, 2023, 8:26AM
- Merck, Eisai Announced That Phase 3 LEAP-001 Trial Of Keytruda Plus Lenvima Did Not Meet Its Dual Primary Endpoints Of Overall Survival And Progression-Free Survival For The First-line Treatment For Patients With Advanced Or Recurrent Endometrial CancerBenzinga Newsdesk - Dec 8, 2023, 6:48AM
Friday, October 13, 2023
Tuesday, October 10, 2023
Monday, September 25, 2023
- Amazon Invests Up To $4B In ChatGPT Competitor, Hollywood Writers Accept Preliminary Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top StoriesVandana Singh - Sep 25, 2023, 10:58AM
- Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment LeqembiVandana Singh - Sep 25, 2023, 10:41AM
Friday, September 22, 2023
- Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung CancerVandana Singh - Sep 22, 2023, 10:21AM
- Merck, Eisai's Two Phase 3 Trials Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) In Certain Types Of Metastatic Non-small Cell Lung Cancer Did Not Meet Its Dual Primary Endpoints Of Overall Survival And Progression-free SurvivalBenzinga Newsdesk - Sep 22, 2023, 6:49AM
Friday, August 25, 2023
Thursday, July 20, 2023
Friday, July 07, 2023
Tuesday, June 13, 2023
Monday, June 12, 2023
Thursday, June 08, 2023
Thursday, May 04, 2023
Friday, April 21, 2023
Monday, April 10, 2023
Monday, April 03, 2023
Friday, March 31, 2023
Thursday, March 16, 2023
Tuesday, March 14, 2023
Monday, March 06, 2023
- Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's TreatmentVandana Singh - Mar 6, 2023, 10:46AM
- FDA Accepted Eisai-Biogen's Supplemental Biologics License Application For Leqembi (Lecanemab-IRMB) 100 mg/ml Injection For Intravenous Use, Supporting The Conversion Of The Accelerated Approval Of Leqembi To A Traditional ApprovalBenzinga Newsdesk - Mar 6, 2023, 3:45AM